← Back to Glaxosmithkline Pharmaceuticals Ltd. overview
Glaxosmithkline Pharmaceuticals Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹3,726 cr | ₹928 cr | ₹54.76 | ₹4,108 cr | ₹1,951 cr | 47.54% | 64.31% | 0.01x | 24.89% |
| FY2024 | ₹3,442 cr | ₹590 cr | ₹34.83 | ₹3,557 cr | ₹1,778 cr | 33.19% | 45.54% | 0.01x | 17.14% |
| FY2023 | ₹3,226 cr | ₹611 cr | ₹36.05 | ₹3,327 cr | ₹1,741 cr | 35.07% | 47.71% | 0.01x | 18.93% |
| FY2022 | ₹3,264 cr | ₹1,695 cr | ₹100.04 | ₹4,633 cr | ₹2,663 cr | 63.64% | 29.11% | 0.01x | 51.92% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.